Neuropathix (NPTX) 10-Q2022 Q1 Quarterly report

Filed: 23 May 22, 4:09pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. sophomore Avg

New words: absence, acetic, acquiror, AICPA, American, Analogue, APIC, article, assay, atopic, attract, azetidine, began, behavior, Behavioral, biological, British, bulk, ceiling, chart, clawed, contrast, cosmeceutical, Dermique, devoid, discretion, earliest, EGC, enjoy, ethoxycarbonyl, fewer, Guide, harbor, hold, hot, hurt, Imputed, iv, key, Lastly, LEA, lessee, linoneyldihydroxybenzyl, long, longer, Method, minimum, modest, modified, morphine, Mouse, Navigating, noncancellable, nonpublic, objective, occupancy, Oncology, palatable, phyto, plate, portfolio, preceding, prescription, prohibited, qualified, qualifying, quantified, ratify, receipt, reclassified, reinforced, Reinforcement, reinforcing, retrospective, safe, senior, sensitivity, Society, specialist, stemming, stretching, Survey, thereof, traditional, undiscounted, unique, uniquely, vendor, wholly

Removed: acquiring, advertising, advisory, al, assessed, aware, behalf, cancellation, cautioned, certificated, Chase, Codification, consultant, contemplate, degree, discharge, divided, Dr, edition, emerge, equally, error, essential, exemption, expiration, fact, Fallon, financially, flexibility, forward, Fox, governed, growth, guidance, imprinted, initial, initially, involuntary, largely, law, legend, license, maximum, measurable, Medicine, member, methodology, milestone, NCE, netted, Neural, occurring, participant, pay, penalty, projected, promulgated, properly, pursing, rapidly, recipient, registered, Regulation, reliably, repaid, represented, reversion, Royalty, salary, scheduled, solicitation, sophisticated, speak, SRC, stating, subleased, subleasee, sublicense, titled, transferred, twelve, uncontrolled, understood, unknown, unrestricted, upfront, vest, vested, voluntary, weight

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

NPTX similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.2

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350 ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Neuropathix, Inc., a Delaware Corporation, (the “Company”) on Form 10-Q for the quarter ended March 31, 2022, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned certify the following pursuant to Section 18, U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002:

1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2. The information contained in the report fairly presents, in all material respects, the financial condition and results of operations of the Company.

	NEUROPATHIX, INC.

Date: May 23, 2022	By:	/s/ Mark Corrao
		Mark Corrao
		Chief Financial Officer (Principal Financial and Accounting Officer)